2023_Outcomes_Digital | Page 51

• % PCI in-hospital mortality rate ( STEMI patients ) – NCDR risk standardized – CathPCI : BSWHVH-D = 1.3 Better than ACC Q32022 90th percentile
• % PCI in-hospital rate of bleeding events non risk adjusted – Cath PCI : BSWHVH-D 0.8 , Better than ACC Q32022 90th percentile
• % Composite : CathPCI Major Adverse Events ( STEMI included ) – CathPCI : BSWHVH-D 1.1 Better than the ACC Q32022 75th percentile
• % CathPCI Major Adverse Events ( STEMI excluded ) – CathPCI : BSWHVH-D 0.5
• % of PCI patients with post procedure stroke – CathPCI : BSWHVH-D 0.0
24

Interventional Cardiology

Baylor Scott & White Heart and Vascular Hospital - Dallas | INTERVENTIONAL CARDIOLOGY
YEAR IN REVIEW ( FY2023 )
Total cardiac cath procedures

13,994

Cath lab cases

5,126

Diagnostic cardiac procedures

3,066

Total percutaneous coronary interventions

1,408

Leading with new treatment options
For cardiovascular disease diagnosis and treatment , innovation leads the way at Baylor Scott & White Heart and Vascular Hospital – Dallas ’ Interventional Cardiology Department .
The Dallas Interventional Cardiology Department has a total of 11 cath labs , wellequipped for both heart and vascular care . Four of the labs are heart and vascular capable , five are EP capable , one is used for endovascular cases , and two are hybrid rooms . The labs offer advanced image quality and radiation lowering equipment for patient and staff safety .
Fiscal Year 2023 “ Firsts ”
• 1st in Texas to use the paclitaxel coated PTCA balloon catheter following the Agent™ study
• 1st new generation SAPIEN X4 TAVR valve implanted in North Texas , 2nd in Texas
• 1st Safari ES ( Extra Support ) implanted in Texas , 3rd in the US
• 1st Evolut FX implanted in Texas
• 1st Navitor TAVR system in North Texas
The department added new treatment options nationally recognized as leading cardiac care with only a few other hospitals across the United States also offering some of the newer procedures and devices . In many instances , the commercial “ firsts ” immediately followed FDA approval as several members of the medical staff were principal investigators for original clinical trials and studies that lead to the FDA approval .
For example , Robert Stoler , MD , FACC , medical director of the catheterization lab at Baylor Scott & White Heart and Vascular Hospital – Dallas , performed several “ firsts ” in Texas and / or the region in fiscal year 2023 . As a part of the ALLIANCE clinical trial , the first in North Texas new generation Sapien X4 TAVR valve was implanted . This was also the second implanted in Texas . The first in Texas Navitor TAVI system was implanted in April 2023 . Notable , the 1st Evolut FX implanted in Texas occurred offering better valve orientation and sealing . This is a selfexpanding transcatheter aortic valve platform designed to bring more precision and control to the TAVR procedure . Pre-market clinical trials were conducted on the Dallas campus .
These examples indicate the continuation of the history for innovation , leading interventional cardiology and valve research and bringing the latest quaternarylevel treatment options to patients who often have complex valvular situations .
For more information on the comprehensive treatments options for valvular disease , see the Center for Valve Disorders information on page 16 .
Percutaneous coronary intervention ( PCI ) performance
At Baylor Scott & White Heart and Vascular Hospital – Dallas , quality and safety metrics related to percutaneous coronary intervention ( PCI ) are analyzed frequently and benchmarks from the National Cardiovascular Database and Registry ( NCDR ) are noted . In fiscal year 2023 , the NCDR ’ s data through Q4 2022 published information ( rolling 4 quarters ) indicated the following : Baylor Scott & White Heart and Vascular Hospital – Dallas ( BSWHVH-D )

• % PCI in-hospital mortality rate ( STEMI patients ) – NCDR risk standardized – CathPCI : BSWHVH-D = 1.3 Better than ACC Q32022 90th percentile

• % PCI in-hospital rate of bleeding events non risk adjusted – Cath PCI : BSWHVH-D 0.8 , Better than ACC Q32022 90th percentile

• % Composite : CathPCI Major Adverse Events ( STEMI included ) – CathPCI : BSWHVH-D 1.1 Better than the ACC Q32022 75th percentile

• % CathPCI Major Adverse Events ( STEMI excluded ) – CathPCI : BSWHVH-D 0.5

• % of PCI patients with post procedure stroke – CathPCI : BSWHVH-D 0.0